Abstract
Combined PET capabilities/CT with 18F-FDG in a comparative assessment of the effect of various variants of targeted therapy was studied in 75 patients with NSCLC with the presence of an activating mutation in the EGFR gene. It is shown that changes in the metabolic activity of the tumor during treatment according to the PERCIST 1.0 criteria are more informative and prognostic value compared with the assessment of the morphological parameters of the tumor according to the RECIST 1.1 criteria. According to PET data/CT with 18F-FDG and analysis of the dynamics of SUVmax and SUVmean, the effect of combined treatment with tyrosine kinase inhibitors in combination with bevacizumab or chemotherapy exceeds the effect of targeted monotherapy in patients with NSCLC with mutations in the EGFR gene, mainly due to a lower frequency of disease progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
